JMP Securities analyst Liisa Bayko noted that Sarepta is scheduled to give an update on its Phase 1/2a study of a micro-dystrophin gene therapy at the World Muscle Society meeting and see hopes to see about 40% micro-dystrophin expression in the fourth patient and at least one vector copy per nucleus, which would be in line with the first three patients. She is also looking for details of the functional benefits that were previously acknowledged, said Bayko, who keeps an Outperform rating and $270 price target on Sarepta shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.